Filgotinib effective in refractory RA
Expert calls for head-to-head comparisons with other therapies
The JAK1 inhibitor filgotinib improves outcomes in patients with active rheumatoid arthritis refractory to disease-modifying anti-rheumatic drug (DMARD) therapy, a clinical trial shows.
Stanford-led researchers evaluated the effects of filgotinib (100mg or 200mg once daily) versus placebo in their study of 448 patients at 114 international sites with moderate to severely active RA and inadequate response or intolerance to one or more prior biologic DMARDs in the phase 3 trial called FINCH-2.
